KR100884493B1 - 위장관을 보호하고 개선된 치료학적 활성을 제공하기위한, 레시틴 오일과 nsaid의 제형을 사용하는 방법및 조성물 - Google Patents
위장관을 보호하고 개선된 치료학적 활성을 제공하기위한, 레시틴 오일과 nsaid의 제형을 사용하는 방법및 조성물 Download PDFInfo
- Publication number
- KR100884493B1 KR100884493B1 KR1020037008167A KR20037008167A KR100884493B1 KR 100884493 B1 KR100884493 B1 KR 100884493B1 KR 1020037008167 A KR1020037008167 A KR 1020037008167A KR 20037008167 A KR20037008167 A KR 20037008167A KR 100884493 B1 KR100884493 B1 KR 100884493B1
- Authority
- KR
- South Korea
- Prior art keywords
- delete delete
- nsaid
- nsaids
- phospholipids
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25671100P | 2000-12-19 | 2000-12-19 | |
| US60/256,711 | 2000-12-19 | ||
| PCT/US2001/051605 WO2002085414A2 (en) | 2000-12-19 | 2001-12-19 | Nsaid formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20030072565A KR20030072565A (ko) | 2003-09-15 |
| KR100884493B1 true KR100884493B1 (ko) | 2009-02-18 |
Family
ID=22973287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020037008167A Expired - Lifetime KR100884493B1 (ko) | 2000-12-19 | 2001-12-19 | 위장관을 보호하고 개선된 치료학적 활성을 제공하기위한, 레시틴 오일과 nsaid의 제형을 사용하는 방법및 조성물 |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1343529B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP4958381B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR100884493B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN102258457B (cg-RX-API-DMAC7.html) |
| AT (1) | ATE414542T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2001297778B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0116380A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2431606C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1110474T1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60136647D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1343529T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2317873T3 (cg-RX-API-DMAC7.html) |
| IL (2) | IL156361A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA03005550A (cg-RX-API-DMAC7.html) |
| PT (1) | PT1343529E (cg-RX-API-DMAC7.html) |
| SI (1) | SI1343529T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002085414A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1653975A4 (en) * | 2003-07-31 | 2006-10-25 | Univ Texas | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING AND / OR PREVENTING CANCER, THE USE OF CANCER OR THE SYMPTOMS OF CANCER |
| US20050176809A1 (en) * | 2004-02-05 | 2005-08-11 | Rodlen Laboratories, Inc. | Method and compositions for treatment of painful disorders |
| WO2005084683A1 (fr) * | 2004-03-03 | 2005-09-15 | MARTINS, José, Araujo | Composition a base de lecithine vegetale, ex. de soja, vitamines du complexe b et d'acide acetylsalicylique, et son utilisation pour la fabrication d'un medicament pour le traitement des maladies neuro-degeneratives |
| KR20070063587A (ko) * | 2004-10-12 | 2007-06-19 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 정제된 인지질-비스테로이드성 소염 약물 연합 조성물 및이의 제조방법 및 사용방법 |
| GB0517673D0 (en) * | 2005-08-31 | 2005-10-05 | Astrazeneca Ab | Formulation |
| CA2626579A1 (en) * | 2005-10-25 | 2007-05-03 | Abbott Laboratories | Formulation comprising a drug of low water solubility and method of use thereof |
| CA2657769C (en) | 2006-07-19 | 2014-11-18 | The Board Of Regents Of The University Of Texas System | Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease |
| WO2009039505A1 (en) * | 2007-09-20 | 2009-03-26 | Rutgers, The State University Of New Jersey | Compositions and methods for treating cardiovascular conditions |
| GB2477590A (en) * | 2010-02-05 | 2011-08-10 | Biocopea Ltd | A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier |
| EP2629779B1 (en) * | 2010-10-22 | 2017-06-21 | Dr. Reddy's Laboratories SA. | Use of storage stable viscous phospholipid depot to treat wounds |
| US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
| US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
| US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| US8895537B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating cardiovascular diseases |
| US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
| US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US9737500B2 (en) | 2010-10-29 | 2017-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| WO2012104655A2 (en) * | 2011-02-04 | 2012-08-09 | Biocopea Limited | Compostions and methods for treating chronic inflammation and inflammatory diseases |
| WO2013022410A2 (en) | 2011-08-08 | 2013-02-14 | Mahmut Bilgic | Production method for effervescent formulations comprising dexketoprofen |
| WO2013049749A2 (en) | 2011-09-29 | 2013-04-04 | Plx Pharma Inc. | pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME |
| US10286093B2 (en) * | 2013-05-23 | 2019-05-14 | Neurosn, Inc. | Method of diagnosing and treating Alzheimer's disease |
| US9446056B2 (en) * | 2014-02-11 | 2016-09-20 | Dr. Reddy's Laboratories Ltd. | Parenteral compositions of celecoxib |
| CN103908454B (zh) * | 2014-04-17 | 2016-08-24 | 兆科药业(广州)有限公司 | 一种药物组合物及其制备方法和应用 |
| WO2016094617A1 (en) * | 2014-12-11 | 2016-06-16 | Phosphorex, Inc. | Aqueous topical drug formulation with controlled release and increased stability |
| CN104739843A (zh) * | 2015-04-15 | 2015-07-01 | 郭志标 | 一种用于治疗口腔溃疡的药物组合物 |
| AU2019231699B2 (en) * | 2018-03-07 | 2023-03-09 | Andrew Xian Chen | Aqueous formulations for insoluble drugs |
| CN108542909B (zh) * | 2018-03-30 | 2020-07-07 | 浙江海昶生物医药技术有限公司 | 一种阿司匹林磷脂固化组合物、其制备方法及药物制剂 |
| JP7229012B2 (ja) * | 2018-12-25 | 2023-02-27 | 小林製薬株式会社 | 内服用医薬組成物 |
| KR20220158031A (ko) | 2020-03-26 | 2022-11-29 | 피엘엑스 옵코 인코포레이티드 | pH 의존성 재구성이 가능한 제약 담체 및 그의 제조 및 사용 방법 |
| CN120643509B (zh) * | 2025-08-18 | 2025-12-05 | 杭州市滨江区浙医二院经血管植入器械研究院 | 血管内长效留存的油相药物溶液及液体灌注球囊传递方式 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5091188A (en) | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
| US5154930A (en) | 1987-03-05 | 1992-10-13 | The Liposome Company, Inc. | Pharmacological agent-lipid solution preparation |
| US5955451A (en) * | 1995-05-12 | 1999-09-21 | The University Of Texas System Board Of Regents | Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60208910A (ja) * | 1984-03-31 | 1985-10-21 | Green Cross Corp:The | 水難溶性薬物・リン脂質複合体の製造方法 |
| JPH07503952A (ja) * | 1992-02-12 | 1995-04-27 | ジヤンセン・シラグ・ソチエタ・ペル・アチオニ | リポソームピロキシカム組成物 |
| EP1214940B1 (en) * | 1995-01-27 | 2009-03-11 | Board of Regents, The University of Texas System | Methods of enhancing the therapeutic activity of NSAIDs and compositions of zwitterionic phospholipids useful therein |
-
2001
- 2001-12-19 AT AT01273758T patent/ATE414542T1/de active
- 2001-12-19 DK DK01273758T patent/DK1343529T3/da active
- 2001-12-19 DE DE60136647T patent/DE60136647D1/de not_active Expired - Lifetime
- 2001-12-19 EP EP01273758A patent/EP1343529B1/en not_active Expired - Lifetime
- 2001-12-19 BR BR0116380-9A patent/BR0116380A/pt not_active Application Discontinuation
- 2001-12-19 WO PCT/US2001/051605 patent/WO2002085414A2/en not_active Ceased
- 2001-12-19 PT PT01273758T patent/PT1343529E/pt unknown
- 2001-12-19 CN CN201110165238.6A patent/CN102258457B/zh not_active Expired - Lifetime
- 2001-12-19 IL IL15636101A patent/IL156361A0/xx unknown
- 2001-12-19 KR KR1020037008167A patent/KR100884493B1/ko not_active Expired - Lifetime
- 2001-12-19 CA CA2431606A patent/CA2431606C/en not_active Expired - Lifetime
- 2001-12-19 CN CNA018223834A patent/CN1543358A/zh active Pending
- 2001-12-19 AU AU2001297778A patent/AU2001297778B2/en not_active Expired
- 2001-12-19 ES ES01273758T patent/ES2317873T3/es not_active Expired - Lifetime
- 2001-12-19 MX MXPA03005550A patent/MXPA03005550A/es active IP Right Grant
- 2001-12-19 SI SI200130899T patent/SI1343529T1/sl unknown
- 2001-12-19 JP JP2002582987A patent/JP4958381B2/ja not_active Expired - Fee Related
-
2003
- 2003-06-09 IL IL156361A patent/IL156361A/en active IP Right Grant
-
2009
- 2009-02-17 CY CY20091100168T patent/CY1110474T1/el unknown
- 2009-11-06 JP JP2009255329A patent/JP2010031044A/ja not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5154930A (en) | 1987-03-05 | 1992-10-13 | The Liposome Company, Inc. | Pharmacological agent-lipid solution preparation |
| US5091188A (en) | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
| US5955451A (en) * | 1995-05-12 | 1999-09-21 | The University Of Texas System Board Of Regents | Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein |
Non-Patent Citations (1)
| Title |
|---|
| 논문 Eur. J. Pharmacology (1985) 외. |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1161107A1 (en) | 2012-08-24 |
| KR20030072565A (ko) | 2003-09-15 |
| EP1343529A2 (en) | 2003-09-17 |
| AU2001297778C1 (en) | 2002-11-05 |
| CA2431606A1 (en) | 2002-10-31 |
| CN102258457A (zh) | 2011-11-30 |
| IL156361A0 (en) | 2004-01-04 |
| MXPA03005550A (es) | 2004-05-14 |
| JP2005506303A (ja) | 2005-03-03 |
| JP4958381B2 (ja) | 2012-06-20 |
| IL156361A (en) | 2011-04-28 |
| PT1343529E (pt) | 2009-02-27 |
| DE60136647D1 (de) | 2009-01-02 |
| WO2002085414A2 (en) | 2002-10-31 |
| ES2317873T3 (es) | 2009-05-01 |
| CY1110474T1 (el) | 2015-04-29 |
| WO2002085414A3 (en) | 2003-05-08 |
| AU2001297778B2 (en) | 2007-05-31 |
| CA2431606C (en) | 2011-07-19 |
| EP1343529B1 (en) | 2008-11-19 |
| CN1543358A (zh) | 2004-11-03 |
| JP2010031044A (ja) | 2010-02-12 |
| CN102258457B (zh) | 2015-07-01 |
| DK1343529T3 (da) | 2009-03-16 |
| ATE414542T1 (de) | 2008-12-15 |
| BR0116380A (pt) | 2005-04-05 |
| SI1343529T1 (sl) | 2009-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20030072565A (ko) | 위장관을 보호하고 개선된 치료학적 활성을 제공하기위한, 레시틴 오일과 nsaid의 제형을 사용하는 방법및 조성물 | |
| US9687551B2 (en) | Compositions comprising lecithin oils and NSAIDs for protecting the gastrointestinal tract and providing enhanced therapeutic activity | |
| AU2001297778A1 (en) | NSAID formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity | |
| US20100173876A1 (en) | Oil-based nsaid compositions and methods for making and using same | |
| EP0287198A2 (en) | Mixtures of polar and neutral lipids for protecting the gastronointestinal tract | |
| JPH09510958A (ja) | 大腸ガンの化学的予防薬剤および化学的治療薬剤としての2−ヒドロキシ−5−フェニルアゾ安息香酸誘導体の使用 | |
| MX2014003890A (es) | Portadores dependientes del ph para la liberacion dirigida de productos farmaceuticos a lo largo del tracto gastrointestinal, composiciones de los mismos, y fabricación y uso de las mismas. | |
| ES2206708T3 (es) | Compuestos citoprotectores. | |
| BRPI0719816B1 (pt) | Uso do fator de crescimento epidérmico (egf) humano para preparar uma composição farmacêutica injetável para a restauração morfofuncional de nervos periféricos em neuropatia diabética e a referida composição | |
| AU2005295874B2 (en) | Purified phospholipid-non-steroidal anti-inflammatory drug associated compositions and methods for preparing and using same | |
| JP4527231B2 (ja) | 平滑筋異常収縮の抑制剤 | |
| HK1161107B (en) | Non-aqueous composition | |
| JP2015209417A (ja) | 経口疾患治療薬 | |
| JP2022506548A (ja) | 化合物の抗pcsk9(抗プロタンパク質変換酵素スブチリシン ケキシン9型)ナノ製剤および心血管疾患の治療および/または予防におけるその使用方法 | |
| TW200936165A (en) | Method and compositions empolying formulations of lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeuticactivity | |
| RU2456979C1 (ru) | Индометацин на основе фосфолипидных наночастиц для применения в офтальмологии |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20030618 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20061219 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20071102 Patent event code: PE09021S01D |
|
| E90F | Notification of reason for final refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Final Notice of Reason for Refusal Patent event date: 20080523 Patent event code: PE09021S02D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20090102 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20090212 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20090213 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20120203 Start annual number: 4 End annual number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20130117 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20130117 Start annual number: 5 End annual number: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20140121 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20140121 Start annual number: 6 End annual number: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20150130 Year of fee payment: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20150130 Start annual number: 7 End annual number: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20160127 Year of fee payment: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20160127 Start annual number: 8 End annual number: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20170119 Year of fee payment: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20170119 Start annual number: 9 End annual number: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20180201 Year of fee payment: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20180201 Start annual number: 10 End annual number: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20190116 Year of fee payment: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20190116 Start annual number: 11 End annual number: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20200115 Year of fee payment: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 20200115 Start annual number: 12 End annual number: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 20210208 Start annual number: 13 End annual number: 13 |
|
| PC1801 | Expiration of term |
Termination date: 20220619 Termination category: Expiration of duration |